The effect of combination therapy with anti-hypertensive drugs on central blood pressure

The effect of combination therapy with anti-hypertensive drugs on central blood pressure - The effect of combination therapy with anti-hypertensive drugs on central blood pressure

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007395

Enrollment

Registered

2012-03-01

Start date

2007-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Olmesartan/Azelnidipine Olmesartan/Amlodipine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with brachial SBP>=140 mmHg and/or DBP>= 90 mmHg received olmesartan monotherapy (20 mg daily) for 12 weeks

Exclusion criteria

Exclusion criteria: 1) secondary hypertension 2) arrhythmia 3) current treatmentfor congestive heart failure 4) a history of stroke or coronary artery disease 5) clinically significant valvular heart disease 6) renal insufficiency (serum creatinine >=2mg/dL) 7) mental disorders severe noncardiovascular disease 8) chronic inflammatory disease

Design outcomes

Primary

Measure	Time frame
Central Blood Pressure Echocardiography	—

Secondary

Measure	Time frame
Augmentation Index Brachial-Ankle Pulse Wave Velocity	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026